Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

US insurance and investment firm, Prudential Financial Inc., and Japanese insurer Dai-ichi Life Holdings have entered into a ...

Prudential Financial and Dai-ichi Life Holdings announced plans to form a strategic partnership focused on product ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on January 19 and set a price ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of speciality chemicals. The Company entered into technical collaboration with the ...

GlobalData is the parent company of Pharmaceutical Technology. Daiichi Sankyo has been particularly active in this field, and ...

Prudential Financial, Inc. and Dai-ichi Life Holdings announced today their intent to pursue a strategic partnership focused on product distribution and asset management capabilities. “As one of the ...